Corcept TherapeuticsCORT +3.03%82 Days Inventory is 407.63 as of Mar. 2026, which is 17% above its 10-year median of 348.32. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 640 Biotechnology companies, Corcept Therapeutics ranks worse than 72.97% on this metric.
The historical rank and industry rank for Corcept Therapeutics's Days Inventory or its related term are showing as below:
CORT'
s Days Inventory Range Over the Past 10 Years
Min: 325.74 Med: 348.32 Max: 389.44
Current: 351.25
During the past 13 years, Corcept Therapeutics's highest Days Inventory was 389.44. The lowest was 325.74. And the median was 348.32.
CORT's Days Inventory is ranked worse than 72.97% of 640
companies
in the Biotechnology industry
Industry Median: 184.145
vs CORT: 351.25
Corcept Therapeutics's Days Inventory
declined
from Mar. 2025 (508.46) to Mar. 2026 (407.63).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Corcept Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.22.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Corcept Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.08.
Corcept Therapeutics (NAS:CORT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Corcept Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Corcept Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Corcept Therapeutics Days Inventory Related Terms
Corcept Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CORT vs PCVX, IBRX, HALO: Days Inventory Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a Days Inventory of 407.63 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Corcept Therapeutics and its competitors. This is 17% above median its historical median of 348.32. Over the past decade, Corcept Therapeutics' Days Inventory has ranged from 325.74 to 389.44. According to the industry distribution chart, Corcept Therapeutics ranks #467 out of 640 companies in the Biotechnology industry, placing it in the top 73%.
Is Corcept Therapeutics' Days Inventory too high?
Corcept Therapeutics' current Days Inventory of 407.63 is 17% above median its 10-year median of 348.32. Over the past 10 years, this metric has ranged from a low of 325.74 to a high of 389.44. The Biotechnology industry median Days Inventory is 184.15. Corcept Therapeutics' value of 407.63 is 121.4% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #467 out of 640 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Days Inventory compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #467 out of 640 companies for Days Inventory. This places Corcept Therapeutics in the lower half of its industry. The industry median Days Inventory is 184.15. Corcept Therapeutics' value of 407.63 is 121.4% above this benchmark. Historically, Corcept Therapeutics' own Days Inventory has ranged from 325.74 to 389.44 over the past decade. While the company's 10-year median is 348.32 vs. the industry median of 184.15, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 184.15, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Days Inventory of 407.63 is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 184.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Days Inventory is 407.63, which is 17% above median its own 10-year median of 348.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.67, compared to a current price of $87.32 — trading 41.6% above its estimated fair value. The current Days Inventory is 407.63, which is 17% above median its 10-year median of 348.32 and 121.4% above the Biotechnology industry median of 184.15. Corcept Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Days Inventory is 407.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $87.32 is trading 41.6% above its estimated GF Value™ of $61.67.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Days Inventory: 407.63 (17% above median its 10-year median of 348.32)
GF Value™: $61.67 vs. price of $87.32 (41.6% above fair value)
Industry Position: 121.4% above the Biotechnology median (#467 of 640)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
